We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study to Assess the Safety and Efficacy of Imiquimod 5% Cream for the Treatment of Actinic Keratosis on the Arms and Hands

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00115154
First Posted: June 22, 2005
Last Update Posted: February 19, 2007
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
Graceway Pharmaceuticals, LLC
  Purpose
The purpose of this study is to evaluate the safety and efficacy of imiquimod 5% cream compared to vehicle cream in the treatment of Actinic Keratosis (AK) on the arm and/or hand when the cream is applied once daily 2 days per week for 16 weeks.

Condition Intervention Phase
Keratosis Drug: Aldara (imiquimod) cream, 5% Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Treatment
Official Title: Vehicle-Controlled, Double-Blind Study to Assess the Safety and Efficacy of Imiquimod 5% Cream for the Treatment of Actinic Keratosis on the Upper Extremities

Resource links provided by NLM:


Further study details as provided by Graceway Pharmaceuticals, LLC:

Primary Outcome Measures:
  • The primary objective of this study is to evaluate the efficacy of imiquimod 5% cream compared to vehicle cream in the treatment of AK on the upper extremities when the cream is applied once daily 2 days per week for 16 weeks.

Secondary Outcome Measures:
  • The secondary objective is to evaluate the safety of treatment with imiquimod 5% cream in subjects with AK lesions on the upper extremities.

Estimated Enrollment: 270
Study Start Date: May 2005
Estimated Study Completion Date: September 2006
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • 18 years of age
  • Have AK on arm or hand
  • Discontinuation of sun tanning and the use of tanning beds
  • Discontinuation of the use of moisturizers, body oils, over-the-counter retinol products and products containing alpha or beta hydroxy acid in the treatment and surrounding area
  • Withholding of the use of sunscreen in the treatment area for 24 hours prior to all study visits and for 8 hours before applying study cream
  • Postponement of the treatment of non-study AK lesions anywhere on the arm being treated until study participation is complete

Exclusion Criteria:

  • Subjects must not have any evidence of systemic cancer or immunosuppression or other unstable health conditions
  • Participation in another clinical study
  • Have previously received treatment with imiquimod within the treatment area
  • Have squamous cell carcinoma (SCC), basal cell carcinoma (BCC), or other malignancy in the treatment or surrounding area that requires treatment
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00115154


Locations
United States, Arizona
Tucson, Arizona, United States, 85710
United States, California
Vista, California, United States, 92083
United States, Georgia
Atlanta, Georgia, United States, 30263
Newnan, Georgia, United States, 30263
United States, Illinois
Buffalo Grove, Illinois, United States, 60089
United States, Indiana
Evansville, Indiana, United States, 47713
United States, New Jersey
Delran, New Jersey, United States, 08075
United States, New York
New York, New York, United States, 10025
Rochester, New York, United States, 14623
United States, North Carolina
Greenville, North Carolina, United States, 27834
United States, Oregon
Portland, Oregon, United States, 97223
United States, Rhode Island
Providence, Rhode Island, United States, 02903
United States, Tennessee
Knoxville, Tennessee, United States, 37922
United States, Texas
Dallas, Texas, United States, 75246
Houston, Texas, United States, 77030
United States, Virginia
Virginia Beach, Virginia, United States, 23454
United States, Washington
Wenatchee, Washington, United States, 98801
United States, Wisconsin
Milwaukee, Wisconsin, United States, 53209
Sponsors and Collaborators
Graceway Pharmaceuticals, LLC
  More Information

ClinicalTrials.gov Identifier: NCT00115154     History of Changes
Other Study ID Numbers: 1516-IMIQ
First Submitted: June 21, 2005
First Posted: June 22, 2005
Last Update Posted: February 19, 2007
Last Verified: February 2007

Keywords provided by Graceway Pharmaceuticals, LLC:
Actinic Keratosis
AK
3M Pharmaceuticals
Aldara
Imiquimod
Actinic Keratosis (AK)

Additional relevant MeSH terms:
Keratosis
Keratosis, Actinic
Skin Diseases
Precancerous Conditions
Neoplasms
Imiquimod
Adjuvants, Immunologic
Immunologic Factors
Physiological Effects of Drugs
Antineoplastic Agents
Interferon Inducers